13.71
Wave Life Sciences Ltd stock is traded at $13.71, with a volume of 1.29M.
It is up +2.01% in the last 24 hours and up +2.85% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$13.44
Open:
$13.57
24h Volume:
1.29M
Relative Volume:
0.20
Market Cap:
$2.55B
Revenue:
$93.95M
Net Income/Loss:
$-129.87M
P/E Ratio:
-15.23
EPS:
-0.9
Net Cash Flow:
$-202.88M
1W Performance:
-5.71%
1M Performance:
+2.85%
6M Performance:
+67.60%
1Y Performance:
+22.08%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
WVE
Wave Life Sciences Ltd
|
13.71 | 2.50B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Innovator with 140% Upside Potential - DirectorsTalk Interviews
How Strong Q4 Revenue Amid Deeper Losses At Wave Life Sciences (WVE) Has Changed Its Investment Story - Yahoo Finance
Wave Life Sciences (WVE) Earnings Call Transcript - AOL.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near - Yahoo Finance
Artisan Partners Limited Partnership Trims Stake in WAVE Life Sciences Ltd. $WVE - MarketBeat
How Mixed Q4 Results, Obesity Data and Cash Runway News At Wave Life Sciences (WVE) Has Changed Its Investment Story - simplywall.st
Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Finviz
Primecap Management Co. CA Has $13.90 Million Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings - Yahoo Finance
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 33,194 Shares of Stock - MarketBeat
Wave Life Sciences (WVE) officer nets 33,194-share sale after option exercises - Stock Titan
WAVE Life Sciences (NASDAQ:WVE) Shares Down 10.6%What's Next? - MarketBeat
WAVE Life Sciences Q4 Earnings Call Highlights - MarketBeat
Decoding WAVE Life Sciences Ltd (WVE): A Strategic SWOT Insight - GuruFocus
Wave Life Sciences (WVE) Quarterly Loss Deepens Bear Narratives On Profitability And Cash Burn - simplywall.st
Wave Life Sciences: Q4 Earnings Snapshot - theheraldreview.com
WAVE Life Sciences Ltd (WVE) Q4 2025 Earnings Call Highlights: N - GuruFocus
Wave Life Sciences at Oppenheimer Conference: Strategic Insights on RNA Medicines - Investing.com Australia
Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Wave Life Sciences Posts Wider FY25 Loss, Highlights Progress Across RNA Pipeline - Nasdaq
Earnings call transcript: Wave Life Sciences Q4 2025 sees revenue drop - Investing.com
Wave Life Sciences (WVE) Reports Strong Q4 Revenue and Advances in Obesity Treatment - GuruFocus
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
WAVE Life Sciences Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Wave Life Sciences: Fourth Quarter Financial Overview - Bitget
Wave Life Sciences Swings to Q4 Net Loss, Revenue Falls - marketscreener.com
Earnings Flash (WVE) Wave Life Sciences Posts Q4 Loss $0.30 a Share, vs. FactSet Est of $0.26 Loss - marketscreener.com
Earnings Flash (WVE) Wave Life Sciences Ltd. Reports Q4 Revenue $17.2M, vs. FactSet Est of $16.1M - marketscreener.com
WAVE LIFE SCIENCES ($WVE) Releases Q4 2025 Earnings - Quiver Quantitative
Wave Life Sciences Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
Wave Life Sciences Ltd earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com India
Wave Life Sciences Highlights 2025 Results and Obesity Progress - TipRanks
Wave Life Sciences Ltd earnings missed by $0.03, revenue topped estimates - Investing.com
Wave Life Sciences Ltd. SEC 10-K Report - TradingView
Earnings Summary: WAVE Life Sciences Q4 - Benzinga
Wave Life Sciences (NASDAQ: WVE) doubles cash, widens 2025 loss on R&D push - Stock Titan
Wave obesity drug WVE-007 shows GLP-1-like fat loss in trial update - Stock Titan
Earnings Preview: WAVE Life Sciences - Benzinga
Investors brace for Wave Life Sciences earnings on obesity bets By Investing.com - Investing.com Canada
Wave Life Sciences Ltd. (WVE) Stock Analysis: Exploring 147% Upside In Biotech Innovation - DirectorsTalk Interviews
WAVE Life Sciences (WVE) Projected to Post Earnings on Tuesday - MarketBeat
A Look At Wave Life Sciences (WVE) Valuation After WVE-006 Rights Return And Obesity Program Spotlight - simplywall.st
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Wave Life Sciences (WVE) Valuation Check After Regaining WVE-006 Rights And New Buy Analyst Coverage - Yahoo Finance
Is Haverty Furniture Companies Inc stock a buy or sell2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Merger Talk: Is Wave Life Sciences Ltd gaining market share2025 Growth vs Value & Safe Entry Trade Signal Reports - baoquankhu1.vn
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):